Sandwich microneedle patch device for rapid compression hemostasis and preparation method of sandwich microneedle patch device

By using a sandwich microneedle patch device after clinical interventional surgery, the problem of excessive hemostasis and compression time is solved, rapid hemostasis and antibacterial effects are achieved, and patients' pain and medical costs are reduced.

CN118892342APending Publication Date: 2024-11-05SHANGHAI PENGSHUO MACHINERY CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411049431.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The prior art has been used to stop bleeding and compress for too long after clinical interventional surgery, resulting in pain, swelling, skin rupture infection and vascular complications in patients, and the hemostatic effect is poor, increasing medical costs and time to stay in the hospital for observation.

Method used

Using a sandwich microneedle patch device, microneedle patches are prepared by dissolving the hemostatic components and using the dual-mold method. Combined with a screw-type or airbag compression device, the microneedle patch can pierce the skin's stratum corneum and release hemostatic drugs and antibacterial materials. , achieve rapid bleeding stop.

Benefits of technology

It significantly reduces the hemostasis time, reduces the incidence of bleeding and hematoma, improves the hemostasis effect, enhances antibacterial properties, and the material has good biocompatibility and degradability, which is safe and reliable.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004974481280000011
    Figure HDA0004974481280000011
  • Figure HDA0004974481280000012
    Figure HDA0004974481280000012
  • Figure HDA0004974481280000013
    Figure HDA0004974481280000013
Patent Text Reader

Abstract

The invention relates to the field of biomedical materials, in particular to the field of A61K9 / 00, and more particularly relates to a sandwich microneedle patch device for rapid compression hemostasis and a preparation method of the sandwich microneedle patch device. The invention provides the combination of a sandwich microneedle technology and compression hemostasis for the first time. According to the method, a sandwich microneedle patch device is used, a pressure surface is in contact with skin for compression, and a sandwich microneedle patch loaded with medicine is adhered to the pressure surface; the obtained hemostasis microneedle patch device is good in hydrophilicity and fast in solubility, the occurrence rate of bleeding and hematoma can be remarkably reduced, the hemostasis time is effectively shortened, and recovery of a patient is accelerated.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedical materials, in particular to the field of A61K9 / 00, and more specifically to a sandwich microneedle patch device for rapid compression hemostasis and a preparation method thereof. Background Art

[0002] Radial artery access and femoral artery access are the main surgical routes for clinical interventional surgery. Compression is usually required for more than 6 hours after radial artery access surgery, and for more than 12 hours after femoral artery access surgery. Currently, the use of physical devices to compress and stop bleeding is the main intervention method after clinical surgery.

[0003] Due to the long compression time, the affected limb is immobilized for a long time, the distal reflux of the compression site is not smooth, and swelling and pain often occur at the distal end of the pressure, which is difficult for patients to tolerate; too long compression time can easily lead to skin ulcer infection and blister formation, especially in elderly patients with loose skin; in addition, long-term compression can easily lead to radial nerve damage and increase the incidence of radial artery occlusion; insufficient compression time or too little pressure will affect the hemostatic effect, easily lead to hematoma at the puncture site, and form serious vascular complications; therefore, after completing interventional examinations or interventional treatments, patients usually need to stay in the hospital for at least 24 hours, which greatly increases the economic cost of medical and health care.

[0004] The mechanical compression devices currently used in clinical practice, such as the prior art CN109276290A, cannot effectively solve the above problems, resulting in great pain for patients after puncture, especially for elderly patients with loose skin, many complications of hemostasis compression, long hospitalization observation time, and high medical costs. Therefore, clinical attempts have been made to combine dressings and drugs with hemostatic functions with physical compression devices in an attempt to speed up the hemostasis time and improve the hemostasis effect, but the clinical effect is not good.

[0005] The skin of human limbs is mainly composed of epidermis, dermis, subcutaneous tissue and blood vessels. Among them, the epidermis is the outermost layer of skin tissue, with a thickness of about 2000μm, and is composed of stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum and stratum basale. The stratum corneum is lipophilic, with a thickness of about 10-40μm, and is a key rate-limiting barrier that affects the effect of hemostatic dressings or hemostatic drugs. How to effectively penetrate the stratum corneum restriction barrier to achieve hemostatic and antibacterial effects is a technical problem that urgently needs to be solved in this field. Summary of the invention

[0006] Nowadays, radial artery access and femoral artery access in clinical surgery require compression for at least 6 hours to stop bleeding after surgery. However, too long a compression time can easily lead to skin rupture and infection at the compression site of the patient, and in severe cases, it can lead to vascular complications and increase the patient's pain. Therefore, it is necessary to improve the compression hemostasis device in clinical practice. To this end, the first aspect of the present invention provides a sandwich microneedle patch device for rapid compression hemostasis; the sandwich microneedle patch device includes a compression device with a sandwich microneedle patch, or a tape, bandage, non-woven fabric, hydrocolloid, or hydrogel with a sandwich microneedle patch, which is compressed by contacting the skin with a pressure surface, and a sandwich microneedle patch loaded with a drug is adhered to the pressure surface; the compression device with a microneedle patch includes a screw-type compression device with an additional sandwich microneedle patch or an airbag compression device with an additional sandwich microneedle patch.

[0007] The second aspect of the present invention provides a method for preparing a sandwich microneedle patch device for rapid compression hemostasis, comprising the following steps: attaching the non-pressure surface of the sandwich microneedle patch to a compression device or adhesive tape, bandage, non-woven fabric, hydrocolloid, or hydrogel.

[0008] Preferably, the method for preparing the sandwich microneedle patch comprises:

[0009] The hemostatic component is dissolved in a solvent, and a uniform hemostatic component solution is prepared by heating and ultrasound; then the sandwich microneedle patch is prepared by a double mold method; first, two molds of different specifications are printed using a 3D printing instrument, namely an outer mold and an inner mold, and then a polydimethylsiloxane solution is cast on the outer mold. After heating and demolding, a female mold made of polydimethylsiloxane is formed. The hemostatic component solution is cast on the female mold so that the solution completely fills the holes in the mold cavity. The hemostatic component solution is completely filled in the holes in the mold cavity by repeated vacuum heat drying operations, and then the inner mold is inserted into the needle body filled with the hemostatic component solution. After drying, the inner mold is removed to form a cavity in the needle body, and then the hemostatic powder is spread in the cavity of the needle body. Finally, the hemostatic component solution is perfused into the substrate to form a backing substrate. After drying, the film is removed to obtain a drug-loaded sandwich hemostatic microneedle.

[0010] Preferably, the hemostatic powder includes, but is not limited to: hemostatic drugs and derivatives, organic or inorganic materials with antibacterial hemostatic effects, Chinese herbal extracts and derivatives, clinical dressings and derivatives.

[0011] Preferably, the hemostatic drugs and their derivatives include: one or more of thrombin, snake venom thrombin, vitamin K, sulfonamide, diacetylaminoacetic acid ethylenediamine, antifibrinolytic drugs, carbachol, posterior pituitary hormone, vasopressin, protamine, tranexamic acid, and hemostatic dressings.

[0012] Preferably, the organic or inorganic material having antibacterial and hemostatic effects includes one or more of potassium permanganate, zeolite, kaolin and montmorillonite.

[0013] Preferably, the Chinese herbal medicine extract and derivatives include: one or more of essential oil, Panax notoginseng, Artemisia argyi, Bletilla striata, and Agrimoniae scabra. Preferably, the clinical dressing and derivatives include: one or more of chitosan, carboxymethyl chitosan, dextran, hyaluronic acid, alginate, gelatin, cellulose, and collagen.

[0014] Preferably, the hemostatic component includes carboxymethyl chitosan, chitosan, dextran, hyaluronic acid, alginate, gelatin, cellulose, collagen, zeolite, kaolin, and montmorillonite.

[0015] Further preferably, the hemostatic component includes carboxymethyl chitosan.

[0016] Preferably, the carboxymethyl chitosan has a degree of deacetylation greater than 70% and a weight average molecular weight greater than 1 million Daltons.

[0017] Further preferably, the degree of deacetylation of the carboxymethyl chitosan is greater than 90%, and the weight average molecular weight is greater than 2 million Daltons; as an implementable case, the carboxymethyl chitosan can be purchased from Shanghai Aladdin, brand: C304739.

[0018] Preferably, the solvent includes: one of distilled water, isopropanol, glycerol, butanediol, carbon tetrachloride, and methanol.

[0019] Further preferably, the solvent comprises distilled water.

[0020] Preferably, the mass concentration of the hemostatic component solution is 5-15%.

[0021] Beneficial Effects

[0022] (1) The present invention proposes for the first time to combine microneedle technology with compression hemostasis, and the prepared hemostatic microneedle patch can achieve rapid hemostasis.

[0023] (2) In the present invention, carboxymethyl chitosan is preferably used as the hemostatic component in the hemostatic microneedle patch, which can effectively stop bleeding and has a certain antibacterial effect. In addition, carboxymethyl chitosan has good biocompatibility and biodegradability, and the hemostatic microneedle patch is safe and reliable to use.

[0024] (3) Carboxymethyl chitosan can effectively stop bleeding and inhibit bacteria. In the present invention, carboxymethyl chitosan with a deacetylation degree greater than 70% and a weight-average molecular weight greater than 1 million Daltons is preferred, which can effectively reduce the theoretical breakage rate of the hemostatic microneedle patch and ensure that the microneedles can effectively puncture the stratum corneum of the skin and quickly stop bleeding. If the deacetylation degree and the weight-average molecular weight are small, the yield strength of the microneedle material after vacuum drying is relatively small, and the puncture performance of the microneedle will be negatively affected.

[0025] (4) The sandwich microneedle patch of the present invention also includes hemostatic powder, which can further improve the hemostatic and antibacterial effects of the microneedles.

[0026] (5) Currently, more than 90% of clinical hemostatic dressings or clinical hemostatic drugs are highly hydrophilic but weakly lipophilic, and cannot effectively penetrate the stratum corneum rate-limiting barrier. Therefore, the present invention selects the microneedle puncture form, which can enable the hemostatic powder drug or hemostatic auxiliary material to effectively penetrate the stratum corneum rate-limiting barrier, quickly stop bleeding and inhibit bacteria.

[0027] (6) Currently, mechanical compression devices are mainly used in medicine to stop bleeding, and the hemostasis time is relatively short. The sandwich microneedle patch provided by the present invention can be used together with a hemostatic compressor, which not only has excellent hemostatic effect, but also can significantly reduce the incidence of bleeding and hematoma, effectively shorten the hemostasis time, and accelerate the patient's recovery.

[0028] (7) The mass concentration of the hemostatic component solution in the present invention is limited to 5-15%. If the mass concentration is too low, the stiffness of the hemostatic microneedle patch will be poor and effective transdermal hemostasis will not be achieved. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 Schematic diagram of the preparation process of the sandwich microneedle patch in Example 1.

[0030] Figure 2 This is a schematic diagram of the appearance of the sandwich microneedle patch in Example 1.

[0031] Figure 3 This is a scanning electron microscope image of the sandwich microneedle patch in Example 1, with a scale of 500 μm.

[0032] Figure 4 This is a test diagram of the mechanical properties of the sandwich microneedle patch and the hollow microneedle in Example 1.

[0033] Figure 5 The dissolution of the sandwich microneedles in Example 1 at different times.

[0034] Figure 6 This is a fluorescence image of the sandwich microneedle transdermal performance test in Example 1.

[0035] Figure 7This is a data chart showing the hemostatic effect of the sandwich microneedle patch in Example 1. DETAILED DESCRIPTION

[0036] Example 1

[0037] The first aspect of this example provides a sandwich microneedle patch device, which is a screw-type compression device with an additional sandwich microneedle patch. The device can contact and compress the skin through a pressure surface, and the sandwich microneedle patch is adhered to the pressure surface.

[0038] The second aspect of this example provides a method for preparing a sandwich microneedle patch device, and the method for preparing the sandwich microneedle patch device is as follows: attaching the non-pressure surface of the sandwich microneedle patch to a screw-type compression device.

[0039] The preparation process of the sandwich microneedle patch is as follows Figure 1 As shown, the preparation steps are specifically as follows:

[0040] The double mold method is adopted. First, two molds of different specifications are printed using a 3D printing instrument, namely an outer mold and an inner mold. Then, a polydimethylsiloxane solution is cast on the outer mold. After heating and demolding, a female mold made of polydimethylsiloxane is formed. A mixed solution of carboxymethyl chitosan and auxiliary materials is cast on the female mold, and the solution is completely filled into the holes in the mold cavity through repeated vacuum heat drying. Then the inner mold is inserted into the needle body filled with the carboxymethyl chitosan mixed solution. After drying, the inner mold is removed to form a cavity in the needle body.

[0041] The carboxymethyl chitosan mixed solution is directly infused into the substrate to form a backing substrate, and the hollow microneedles are obtained by removing the film after drying.

[0042] After the cavity is filled with tranexamic acid drug powder, the carboxymethyl chitosan mixed solution is infused into the substrate to form a backing substrate. After drying, the film is removed to obtain the tranexamic acid sandwich microneedle.

[0043] The mixed solution of carboxymethyl chitosan and its auxiliary materials is a mixed aqueous solution of carboxymethyl chitosan with a mass concentration of 5%, polyvinyl pyrrolidone with a mass concentration of 20% and polyvinyl alcohol with a mass concentration of 6%, which is obtained by heating and ultrasonically removing bubbles.

[0044] The carboxymethyl chitosan has a deacetylation degree greater than 90% and a weight average molecular weight of 2.4 million Daltons and is purchased from Shanghai Aladdin with the brand name C304739.

[0045] Figure 2 This is a real picture of the appearance of the sandwich microneedle patch.

[0046] Figure 3 This is the microscopic morphology of the sandwich microneedle.

[0047] Comparative Example 1

[0048] The specific implementation of this example is the same as that of Example 1, except that in this example, no hemostatic powder is added during the preparation of the microneedle patch, which is recorded as hollow microneedles.

[0049] Performance Testing

[0050] Test 1: Microscopic morphology test

[0051] In order to observe the condition of the hemostatic microneedle patch needle body in Example 1, the spatial distribution of the microneedles, the array and the height of the microneedles; the dried microneedle sample was directly adhered to the conductive glue, and then gold spraying test was performed: the Oxford Quorum SC7620 sputtering coater was used to spray gold for 45 seconds, and the gold spraying current was 10mA; then the sample morphology test was taken using a TESCAN MIRA LMS scanning electron microscope, and the acceleration voltage was 3kV when the morphology was taken. The results are shown in Figure 1. Figure 3 The prepared microneedle patch is composed of 49 (7×7) needles on a bottom plate, with a height of 1000±10 μm, a base width of 900±10 μm, and a center space of 573±5 μm between adjacent needles. The needle body presents a conical shape, uniform size, and sharp tip.

[0052] Test 2: Mechanical properties test

[0053] The microneedle was compressed by a precision probe to obtain the stress-strain curve. The sample was subjected to compression test using a P / 20Rmm cylindrical probe. The specific method parameters were as follows: test speed 0.1mm / s (sample size: thickness 2000mm, surface area 100mm 2 )Test method: Use constant compression rate mode to perform vertical compression test on the microneedle. The theoretical breaking force of the microneedle can be measured from the force-displacement curve of Jiangsu Jicui Precision Nanoindenter, and compared with the penetration force required for the skin, to determine whether the microneedle can penetrate the skin. When the yield force of the microneedle is less than the skin puncture force, the microneedle will break before penetrating the skin and will not be able to pierce the skin. Therefore, the skin puncture force should be measured and compared with the yield force of the microneedle to predict the puncture effectiveness of the microneedle. See the yield stress change diagram corresponding to the test in Example 1 for details. Figure 4 .

[0054] It can be seen that the single needle yield force of the hollow microneedle and the sandwich microneedle in Example 1 is much greater than the minimum force of 58 mN required to penetrate the skin, indicating that the sandwich microneedle can penetrate the skin.

[0055] Test 3: Microneedle dissolution test

[0056] To further evaluate the dissolution of the microneedles, methylene blue dye was added to the microneedles to facilitate observation of the dissolution of the microneedles. The dissolution of the microneedles at different times was observed. Figure 5 As shown in the figure, compared with 0s, the microneedle tip was obviously dissolved after 30s, and the microneedle body was almost completely dissolved after 60s. This shows that the microneedle has good dissolution performance.

[0057] Test 4: Transdermal performance test

[0058] The microneedle material was labeled with rhodamine B fluorescence, and then the CLSM confocal microscope was used to observe the penetration depth of the microneedle. A sandwich microneedle patch containing rhodamine B was prepared. The sandwich microneedle patch was inserted into the skin of a miniature pig and the microneedle patch was removed after 60 seconds. The red fluorescence signal of rhodamine B was further observed using CLSM. The longitudinal fluorescence scan of the pig skin Figure 6 The red fluorescence signal can be clearly observed in the image. Obviously, the sandwich microneedle patch can pierce the stratum corneum.

[0059] Test 5: Hemostasis effect test

[0060] The sandwich microneedle patch is placed in contact with the skin wound and completely covers it. A screw-type compressor is used to adjust the contact surface pressure by screwing. With the help of the rigidity of the microneedles, the microneedles penetrate the stratum corneum of the skin. With the help of the rapid disintegration and metabolism of the microneedle components in the epidermal tissue fluid and on the skin surface, a sterile covering layer of the wound is formed under physical pressure. The microneedle material can cover and block the wound, and release it to the superficial tissue under the epidermis. With the help of physical pressure, the activated clotting time (ACT value) around the bleeding point is quickly reduced to achieve a rapid hemostasis effect. Figure 7 As shown: using the hemostatic microneedle patch provided in Example 1 of the present invention in combination with a screw-type compressor can significantly reduce the compression time and reduce the incidence of bleeding and hematoma compared to using only a screw-type compressor under the same pressure.

Claims

1. A sandwich microneedle patch device for rapid compression hemostasis, characterized in that: It includes a compression device with a sandwich microneedle patch, or an adhesive tape, bandage, non-woven fabric, hydrocolloid, or hydrogel with a sandwich microneedle patch; the sandwich microneedle patch exerts compression by contacting the skin with a pressure surface, and the pressure surface is adhered with sandwich microneedles.

2. A method for preparing the sandwich microneedle patch device according to claim 1, characterized in that: include: The non-pressure surface of the sandwich microneedle patch is attached to a compression device or adhesive tape, bandage, non-woven fabric, hydrocolloid, or hydrogel to obtain the patch.

3. The method for preparing the sandwich microneedle patch device according to claim 2, characterized in that: The method for preparing the sandwich microneedle patch comprises the following steps: The hemostatic component and auxiliary materials are dissolved in a solvent, and a uniform hemostatic component solution is prepared by heating and ultrasound; then a double mold method is used to prepare a sandwich microneedle patch; first, two molds of different specifications are printed out using a 3D printing instrument, namely an outer mold and an inner mold, and then a polydimethylsiloxane solution is cast on the outer mold, and after heating and demolding, a female mold made of polydimethylsiloxane is formed; the hemostatic component solution is cast on the female mold so that the solution completely fills the holes in the mold cavity; repeated vacuum heat drying operations are used to completely fill the holes in the mold cavity with the hemostatic component solution, and then the inner mold is inserted into the needle body filled with the hemostatic component solution, and after drying, the inner mold is removed to form a cavity in the needle body, and then the cavity of the needle body is covered with hemostatic powder, and finally the hemostatic component solution is poured into the substrate to form a backing substrate, and after drying, the film is removed to obtain a drug-loaded sandwich hemostatic microneedle.

4. The method for preparing the sandwich microneedle patch device according to claim 3, characterized in that: The hemostatic powder in the sandwich microneedle material includes one or more of: hemostatic drugs and derivatives, organic materials or inorganic materials with antibacterial and hemostatic effects, Chinese medicine extracts and derivatives, clinical dressings and derivatives.

5. The method for preparing the sandwich microneedle patch device according to claim 4, characterized in that: The hemostatic drugs and their derivatives include: one or more of thrombin, snake venom hemocoagulase, vitamin K, sulfonamide, diacetylaminoacetic acid ethylenediamine, antifibrinolytic drugs, carbachol, posterior pituitary hormone, vasopressin, protamine, tranexamic acid, and hemostatic dressings.

6. The method for preparing the sandwich microneedle patch device according to claim 5, characterized in that: The organic or inorganic material with antibacterial and hemostatic effects includes one or more of potassium permanganate, zeolite, kaolin and montmorillonite.

7. The method for preparing the sandwich microneedle patch device according to claim 6, characterized in that: The Chinese medicine extract and derivatives include: essential oil, Panax notoginseng, Artemisia argyi, Bletilla striata, Agrimoniae scabra and one or more of them.

8. The method for preparing the sandwich microneedle patch device according to claim 7, characterized in that: The clinical dressing and its derivatives include one or more of chitosan, carboxymethyl chitosan, dextran, hyaluronic acid, alginate, gelatin, cellulose and collagen.

9. The method for preparing the sandwich microneedle patch device according to claim 8, characterized in that: The mass concentration of the hemostatic component in the hemostatic component solution is 5-15%.

10. The method for preparing the sandwich microneedle patch device according to claim 9, characterized in that: The hemostatic component includes one or more of chitosan, carboxymethyl chitosan, dextran, hyaluronic acid, alginate, gelatin, cellulose, collagen, zeolite, kaolin and montmorillonite.

Citation Information

Cited By

  • Electrode assembly and electric coagulation hemostasis device thereof

    CN120203753A